Skip to main content
Clinical Trials/NCT02022813
NCT02022813
Completed
Not Applicable

Impact of Supplemental Parenteral Nutrition (SPN) on Energy Balance, and Infection Rate in Intensive Care Patients: Underlying Metabolic, Inflammatory and Immune Mechanisms.

Centre Hospitalier Universitaire Vaudois2 sites in 1 country28 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Critical Illness
Sponsor
Centre Hospitalier Universitaire Vaudois
Enrollment
28
Locations
2
Primary Endpoint
Glucose and Leucine turnover
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Having previously demonstrated that supplemental parenteral nutrition to complete an insufficient enteral nutrition (EN) between D4 and D8 improves outcome after critical illness, by reducing infectious complications, the present trial aims at investigating the underlying carbohydrate and protein metabolism changes, as well as the immune and inflammatory modulations associated with this improvement.

Detailed Description

Enrollment on day 3 of critically ill patients, without contraindication to EN, not achieving 60% of the ICU per protocol energy target. Intervention: Randomization to either continued pure EN, or from day 4 to supplemental PN to complete EN at target validated by indirect calorimetry. Measurements: Indirect calorimetry on Days 3, 4, 9 (twice). Primary endpoints = glucose and leucine metabolism On days 4 and 9-10: isotopic investigation of glucose metabolism, and immune and inflammatory responses// Day 9-10: isotopic investigation of protein (leucine) metabolism Secondary endpoints: Insulin requirements, area under the curve (AUC) of blood Glucose, infections after day 9, overall complications, length of mechanical ventilation, of ICU and hospital stay.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
June 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mette M Berger

Prof

Centre Hospitalier Universitaire Vaudois

Eligibility Criteria

Inclusion Criteria

  • estimated duration of ICU stay \> 5 days,
  • estimated survival \> 7 days,
  • absence of contraindication to EN
  • need for mechanical ventilation
  • informed consent obtained from patients, close relative, or referring physician

Exclusion Criteria

  • refusal of the patient or of the next of kin
  • age \< 18 years
  • non-functional digestive tract (short bowel, persistent ileus, proximal intestinal fistula high rate \> 1.5 litres/day)
  • already receiving PN before Day 3
  • absence of a central venous catheter
  • women who are pregnant (pregnancy test).
  • Admission after cardiac arrest, or severe brain injury

Outcomes

Primary Outcomes

Glucose and Leucine turnover

Time Frame: 10 days

On D04:Infusion after priming of 6.6 2H2 glucose and NaH13CO3 On Day 09-10: Infusion after priming of NaH13CO3 and of L-\[1-13C\]-Leucine + repeat of the glucose sequence

Secondary Outcomes

  • Immune and inflammatory impact of optimized target feeding(10 days)

Study Sites (2)

Loading locations...

Similar Trials